Glucagon receptor antagonist ups blood pressure in T2DM

February 23, 2017

(HealthDay)—For patients with type 2 diabetes, once-daily treatment with the glucagon receptor antagonist LY2409021 is associated with increases in ambulatory blood pressure (BP), according to a study published online Feb. 13 in Diabetes, Obesity and Metabolism.

Christof M. Kazda, M.D., Ph.D., from Eli Lilly and Company in Neuilly-sur-Seine, France, and colleagues conducted a six-week randomized trial to examine the effects of once-daily administration of LY2409021 versus on (SBP), diastolic BP (DBP), and mean arterial pressure (MAP) using 24-hour ambulatory BP monitoring. Participants included 270 patients with type 2 diabetes treated with diet/exercise ± metformin.

The researchers found that 24-hour mean SBP was increased after six weeks of LY2409021 treatment, with a least squares mean (LSM) difference of 2.26 mm Hg versus placebo (95 percent confidence interval [CI], 1.11 to 3.40; P < 0.001). There were also increases in 24-hour mean DBP and MAP, with LSM differences of 1.37 mm Hg and 1.67 mm Hg, respectively, versus placebo (95 percent CIs, 0.66 to 2.08 and 0.86 to 2.47, respectively; both P < 0.001). LY2409021 treatment correlated with reduced hemoglobin A1c (HbA1c) levels at week six, with a LSM difference of −0.49 percent versus placebo (95 percent CI, −0.56 to −0.42 percent; P < 0.001). LY2409021 treatment correlated with small but significant changes in serum lipid and aminotransferase levels (all P < 0.05 versus placebo).

"Statistically significant increases in BP, MAP, and were observed with LY2409021 at a dose that lowered HbA1c and glucose levels," the authors write. "These effects may limit the clinical utility of LY2409021."

Several authors disclosed financial ties to Eli Lilly, which developed LY2409021 and funded the study.

Explore further: Valsartan cuts microalbuminuria in impaired glucose tolerance

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Valsartan cuts microalbuminuria in impaired glucose tolerance

February 9, 2017
(HealthDay)—For patients with impaired glucose tolerance (IGT), valsartan is associated with reduced incidence of microalbuminuria, according to a study published online Jan. 17 in Diabetes, Obesity and Metabolism.

Baricitinib associated with significant improvement in RA

February 20, 2017
(HealthDay)—For patients with rheumatoid arthritis who have had an inadequate response to methotrexate, baricitinib is associated with significant clinical improvements, compared to either placebo or adalimumab, according ...

Greater drop in hemoglobin A1c with empagliflozin plus metformin

August 16, 2016
(HealthDay)—Twenty-four weeks of empagliflozin + metformin correlates with a significantly greater reduction in hemoglobin A1c (HbA1c) compared with once-daily empagliflozin or twice-daily metformin, according to a study ...

Insulin glargine 300 U/mL beats glargine 100 U/mL in T1DM

January 31, 2017
(HealthDay)—For patients with type 1 diabetes, receipt of insulin glargine 300 U/mL (Gla-300) is associated with better glucose control than glargine 100 U/mL (Gla-100), regardless of injection time, according to a study ...

Exenatide twice daily deemed efficacious across BMI ranges

April 11, 2016
(HealthDay)—For patients with type 2 diabetes, exenatide twice daily added to insulin glargine is efficacious across body mass index (BMI) ranges, according to a study published online March 29 in Diabetes, Obesity and ...

Ranolazine added to glimepiride cuts HbA1c in T2DM

January 18, 2016
(HealthDay)—For patients with type 2 diabetes on background glimepiride therapy, but not metformin, addition of ranolazine is associated with a significant reduction in hemoglobin A1c (HbA1c), according to research published ...

Recommended for you

Moderate exercise before conception resulted in lower body weight, increased insulin sensitivity of offspring

October 22, 2018
Men who want to have children in the near future should consider hitting the gym.

A novel insulin accelerant

October 17, 2018
Insulin levels rise after eating a meal, signaling uptake of circulating glucose by skeletal muscle. In individuals with diabetes this process is often impaired—a condition known as insulin resistance.

Fat tissue may play a crucial role in the progression of diabetes, challenging long established notions

October 12, 2018
A new study by Australian researchers, out today, is challenging what we know about the causes of diabetes. The new research points to fat tissue as a source of disease, and widens our understanding beyond the traditional ...

Does breastfeeding hormone protect against type 2 diabetes?

October 12, 2018
(HealthDay)—The hormone prolactin—most commonly associated with breastfeeding—may play a role in reducing the risk of type 2 diabetes, a new study suggests.

Planned intermittent fasting may help reverse type 2 diabetes, suggest doctors

October 10, 2018
Planned intermittent fasting may help to reverse type 2 diabetes, suggest doctors writing in the journal BMJ Case Reports after three patients in their care, who did this, were able to cut out the need for insulin treatment ...

Markers of dairy fat consumption linked to lower risk of type two diabetes

October 10, 2018
Higher levels of biomarkers of dairy fat consumption are associated with a lower risk of developing type 2 diabetes, according to new research published today in PLOS Medicine. The study, in more than 60,000 adults, was undertaken ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.